617 related articles for article (PubMed ID: 31168016)
1. [Emicizumab, a bispecific antibody mimicking factor VIII: a novel alternative therapy for hemophilia A with inhibitors].
Nogami K
Rinsho Ketsueki; 2019; 60(5):475-479. PubMed ID: 31168016
[TBL] [Abstract][Full Text] [Related]
2. [Emicizumab: a paradigm shift in hemophilia treatment].
Nogami K
Rinsho Ketsueki; 2020; 61(5):536-541. PubMed ID: 32507821
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibody mimicking factor VIII.
Nogami K
Thromb Res; 2016 May; 141 Suppl 2():S34-5. PubMed ID: 27207420
[TBL] [Abstract][Full Text] [Related]
4. [A bispecific antibody mimicking factor VIII in hemophilia A therapy].
Nogami K
Rinsho Ketsueki; 2016 Jun; 57(6):709-14. PubMed ID: 27384849
[TBL] [Abstract][Full Text] [Related]
5. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
[TBL] [Abstract][Full Text] [Related]
6. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
[TBL] [Abstract][Full Text] [Related]
7. Emicizumab: A Review in Haemophilia A.
Blair HA
Drugs; 2019 Oct; 79(15):1697-1707. PubMed ID: 31542880
[TBL] [Abstract][Full Text] [Related]
8. New therapies using nonfactor products for patients with hemophilia and inhibitors.
Nogami K; Shima M
Blood; 2019 Jan; 133(5):399-406. PubMed ID: 30559263
[TBL] [Abstract][Full Text] [Related]
9. Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions.
Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
Thromb Haemost; 2021 Mar; 121(3):279-286. PubMed ID: 32906155
[TBL] [Abstract][Full Text] [Related]
10. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
[TBL] [Abstract][Full Text] [Related]
11. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
Mahlangu JN
BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
[TBL] [Abstract][Full Text] [Related]
12. Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A.
Le Quellec S
Drug Des Devel Ther; 2020; 14():469-481. PubMed ID: 32099331
[TBL] [Abstract][Full Text] [Related]
13. Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.
Díaz-Ricart M; Isola IM; Escolar G
Drugs Today (Barc); 2018 Oct; 54(10):591-600. PubMed ID: 30398480
[TBL] [Abstract][Full Text] [Related]
14. Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab.
Yada K; Nogami K
Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1148-1154. PubMed ID: 32237902
[TBL] [Abstract][Full Text] [Related]
15. Emicizumab-kxwh: First Global Approval.
Scott LJ; Kim ES
Drugs; 2018 Feb; 78(2):269-274. PubMed ID: 29357074
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
[TBL] [Abstract][Full Text] [Related]
17. Emicizumab: Review of the literature and critical appraisal.
Rodriguez-Merchan EC; Valentino LA
Haemophilia; 2019 Jan; 25(1):11-20. PubMed ID: 30431213
[TBL] [Abstract][Full Text] [Related]
18. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.
Levy GG; Asikanius E; Kuebler P; Benchikh El Fegoun S; Esbjerg S; Seremetis S
J Thromb Haemost; 2019 Sep; 17(9):1470-1477. PubMed ID: 31124272
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
[TBL] [Abstract][Full Text] [Related]
20. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.
Gelbenegger G; Schoergenhofer C; Knoebl P; Jilma B
Thromb Haemost; 2020 Oct; 120(10):1357-1370. PubMed ID: 32717759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]